Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Unusually High Volume Points to Upside in These Stocks
07:46am, Friday, 05'th Apr 2024
If investing were easy, everybody would do it, and we would all be rich. But that isn't the case.
NEEDHAM, Mass., April 04, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializin
Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
08:05am, Thursday, 28'th Mar 2024
NEEDHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
04:30pm, Tuesday, 05'th Mar 2024
NEEDHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
07:30am, Tuesday, 13'th Feb 2024
NEEDHAM, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic
Approaching 6 anticipated data readouts across 3 platforms in 2024, including survival data in non-small cell lung cancer (NSCLC) and a potentially registrational phase 3 clinical trial in prostate ca
Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409
01:32pm, Wednesday, 13'th Dec 2023
The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.
Candel Therapeutics pancreatic cancer therapy awarded FDA Fast Track Designation
11:31am, Tuesday, 12'th Dec 2023
Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Design
Candel Therapeutics pancreatic cancer therapy awarded FDA Fast Track Designation
11:31am, Tuesday, 12'th Dec 2023
Candel Therapeutics shares gained more than 37% after the biopharmaceutical firm announced that its pancreatic cancer therapeutic has received U.S. Food and Drug Administration (FDA) Fast Track Design
NEEDHAM, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapi
Candel Therapeutics Upcoming Investor Conference Participation for November
08:00am, Tuesday, 01'st Nov 2022
NEEDHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul
Candel Therapeutics Upcoming Investor Conference Participation
08:00am, Tuesday, 06'th Sep 2022
NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today ann
Candel Therapeutics signs $25M non-dilutive debt financing agreement with Silicon Valley Bank
01:47pm, Tuesday, 01'st Mar 2022 Seeking Alpha
Candel Therapeutics (CADL) entered into a loan and security agreement with Silicon Valley Bank for $25M, $20M of which will be available immediately; additional $5M will be available in…
Bionaut Labs and Candel Therapeutics Announce Strategic Collaboration in Precision-Targeted Delivery of Oncolytic Viral Immunotherapies
10:00am, Wednesday, 15'th Dec 2021 Intrado Digital Media
LOS ANGELES and NEEDHAM, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Bionaut Labs, a company focused on revolutionizing the treatment of central nervous system disorders (CNS) with its Bionaut precision medicine treatment modality, and Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical-stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced a strategic collaboration to investigate the use of Bionauts remote-controlled microscale robots for precision delivery of Candels oncolytic viral immunotherapy agents to specific brain tumors.
